GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Raily Aesthetic Medicine International Holdings 2135.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

0.09

—

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Raily Aesthetic Medicine International Holdings

Its shares trade on HKEX under the ticker 2135.HK. It has been listed since 28 December 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥184.5m and net income of CN¥1.8m. At that date it held total assets of CN¥237.8m and shareholders' equity of CN¥107.9m.

Raily Aesthetic Medicine International Holdings Ltd. is an investment holding company, which engages in the provision of aesthetic medical services and consulting services. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2020-12-28. The firm mainly operates through two segments. The Aesthetic Medical Services segment mainly includes inpatient services, including surgical services and outpatient services (including injection service, dermatology service and others). The Consulting Services segment principally includes management consulting services and aesthetic training courses. The firm mainly conducts business within the domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Providers & Services
Listed since
28 Dec 2020
Employees
321
Website
ruilizx.com ↗

Leadership

Pay as last reported

  • Mr. Haishu FuExecutive Chairman of the Board, since 2018CN¥401,000
  • Mr. Jianliang SongChief Executive Officer, Executive Director, since 2019CN¥1.4m
  • Ms. Chunxiu ZhangChief Financial Officer
  • Mr. Ying WangExecutive Director, since 2021CN¥259,000
  • Ms. Qirui FanNon-Executive Director
  • Mr. Dequan CaoNon-Executive Independent DirectorCN¥147,000
  • Mr. Teng LiuNon-Executive Independent DirectorCN¥147,000
  • Ms. Xiaofen YangNon-Executive Independent DirectorCN¥147,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The company operates in the growing aesthetic medical sector.
  • It has a dedicated workforce of 321 full-time employees.
  • Business is conducted primarily within the domestic market.

Weaknesses

  • The firm is an investment holding company with limited operational depth.
  • Services are restricted to two specific business segments.
  • Management consulting is a minor part of the overall offering.

Opportunities

  • Expanding outpatient services like dermatology could increase revenue.
  • Training courses offer potential for broader market reach.
  • Consulting services may attract new clinic partnerships.

Threats

  • Regulatory changes in the health care sector pose risks.
  • Competition in the aesthetic medical industry is intensifying.
  • Reliance on the domestic market limits international growth.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.